These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19770002)

  • 41. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of GABA agonists on body temperature regulation in GABA(B(1))-/- mice.
    Quéva C; Bremner-Danielsen M; Edlund A; Ekstrand AJ; Elg S; Erickson S; Johansson T; Lehmann A; Mattsson JP
    Br J Pharmacol; 2003 Sep; 140(2):315-22. PubMed ID: 12970075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-amnesic properties of (+/-)-PPCC, a novel sigma receptor ligand, on cognitive dysfunction induced by selective cholinergic lesion in rats.
    Antonini V; Prezzavento O; Coradazzi M; Marrazzo A; Ronsisvalle S; Arena E; Leanza G
    J Neurochem; 2009 May; 109(3):744-54. PubMed ID: 19245662
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Receptor subtype-dependent positive and negative modulation of GABA(A) receptor function by niflumic acid, a nonsteroidal anti-inflammatory drug.
    Sinkkonen ST; Mansikkamäki S; Möykkynen T; Lüddens H; Uusi-Oukari M; Korpi ER
    Mol Pharmacol; 2003 Sep; 64(3):753-63. PubMed ID: 12920213
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers.
    Sternfeld F; Carling RW; Jelley RA; Ladduwahetty T; Merchant KJ; Moore KW; Reeve AJ; Street LJ; O'Connor D; Sohal B; Atack JR; Cook S; Seabrook G; Wafford K; Tattersall FD; Collinson N; Dawson GR; Castro JL; MacLeod AM
    J Med Chem; 2004 Apr; 47(9):2176-9. PubMed ID: 15084116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibiting α5 Subunit-Containing γ-Aminobutyric Acid Type A Receptors Attenuates Cognitive Deficits After Traumatic Brain Injury.
    Khodaei S; Avramescu S; Wang DS; Sheng H; Chan NK; Lecker I; Fernandez-Escobar A; Lei G; Dewar MB; Whissell PD; Baker AJ; Orser BA
    Crit Care Med; 2020 Apr; 48(4):533-544. PubMed ID: 32205600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist.
    Atack JR; Hallett DJ; Tye S; Wafford KA; Ryan C; Sanabria-Bohórquez SM; Eng WS; Gibson RE; Burns HD; Dawson GR; Carling RW; Street LJ; Pike A; De Lepeleire I; Van Laere K; Bormans G; de Hoon JN; Van Hecken A; McKernan RM; Murphy MG; Hargreaves RJ
    J Psychopharmacol; 2011 Mar; 25(3):329-44. PubMed ID: 20156926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties.
    Chambers MS; Atack JR; Carling RW; Collinson N; Cook SM; Dawson GR; Ferris P; Hobbs SC; O'connor D; Marshall G; Rycroft W; Macleod AM
    J Med Chem; 2004 Nov; 47(24):5829-32. PubMed ID: 15537339
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics and metabolism studies on (3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy) pyrazolo[1,5-d][1,2,4]triazine, a functionally selective GABA(A) alpha5 inverse agonist for cognitive dysfunction.
    Jones P; Atack JR; Braun MP; Cato BP; Chambers MS; O'Connor D; Cook SM; Hobbs SC; Maxey R; Szekeres HJ; Szeto N; Wafford KA; MacLeod AM
    Bioorg Med Chem Lett; 2006 Feb; 16(4):872-5. PubMed ID: 16303300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GABA(A) receptor subtype selective cognition enhancers.
    Maubach K
    Curr Drug Targets CNS Neurol Disord; 2003 Aug; 2(4):233-9. PubMed ID: 12871033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans.
    Atack JR; Wong DF; Fryer TD; Ryan C; Sanabria S; Zhou Y; Dannals RF; Eng WS; Gibson RE; Burns HD; Vega JM; Vessy L; Scott-Stevens P; Beech JS; Baron JC; Sohal B; Schrag ML; Aigbirhio FI; McKernan RM; Hargreaves RJ
    J Pharmacol Exp Ther; 2010 Jan; 332(1):17-25. PubMed ID: 19779131
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ONO-8590580, a Novel GABA
    Kawaharada S; Nakanishi M; Nakanishi N; Hazama K; Higashino M; Yasuhiro T; Lewis A; Clark GS; Chambers MS; Maidment SA; Katsumata S; Kaneko S
    J Pharmacol Exp Ther; 2018 Jul; 366(1):58-65. PubMed ID: 29674331
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treating enhanced GABAergic inhibition in Down syndrome: use of GABA α5-selective inverse agonists.
    Martínez-Cué C; Delatour B; Potier MC
    Neurosci Biobehav Rev; 2014 Oct; 46 Pt 2():218-27. PubMed ID: 24412222
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a partial agonist.
    Van Laere K; Bormans G; Sanabria-Bohórquez SM; de Groot T; Dupont P; De Lepeleire I; de Hoon J; Mortelmans L; Hargreaves RJ; Atack JR; Burns HD
    Biol Psychiatry; 2008 Jul; 64(2):153-61. PubMed ID: 18339360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023.
    Atack JR
    Adv Pharmacol; 2009; 57():137-85. PubMed ID: 20230761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Selective GABA(A) α5 positive allosteric modulators improve cognitive function in aged rats with memory impairment.
    Koh MT; Rosenzweig-Lipson S; Gallagher M
    Neuropharmacology; 2013 Jan; 64(1):145-52. PubMed ID: 22732440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic Treatment with a Promnesiant GABA-A α5-Selective Inverse Agonist Increases Immediate Early Genes Expression during Memory Processing in Mice and Rectifies Their Expression Levels in a Down Syndrome Mouse Model.
    Braudeau J; Dauphinot L; Duchon A; Loistron A; Dodd RH; Hérault Y; Delatour B; Potier MC
    Adv Pharmacol Sci; 2011; 2011():153218. PubMed ID: 22028705
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cognitive enhancement by pharmacological and behavioral interventions: the murine Down syndrome model.
    Möhler H
    Biochem Pharmacol; 2012 Oct; 84(8):994-9. PubMed ID: 22898099
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Contribution of GABA
    Paine TA; Chang S; Poyle R
    Behav Brain Res; 2020 Jan; 378():112261. PubMed ID: 31560920
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An 5 GABAA Receptor Inverse Agonist, 5IA, Attenuates Amyloid Beta-Induced Neuronal Death in Mouse Hippocampal Cultures.
    Vinnakota C; Govindpani K; Tate WP; Peppercorn K; Anekal PV; Waldvogel HJ; Faull RLM; Kwakowsky A
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32384683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.